Skip to content

A Population-based Study of Drug Exposures and Adverse Pregnancy Outcomes in China (DEEP)

A Population-based Study of Drug Exposures and Adverse Pregnancy Outcomes in China (DEEP)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05620056
Enrollment
564760
Registered
2022-11-17
Start date
2013-01-01
Completion date
2022-11-01
Last updated
2022-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital Malformation, Drug Exposure, Pregnancy

Keywords

Cohort study, drug exposures, congenital malformation, pregnancy, population-based

Brief summary

The DEEP cohort is the first population-based cohort of pregnant population in China that longitudinally documents drug uses throughout the pregnancy life course and adverse pregnancy outcomes.

Detailed description

The DEEP cohort is the first population-based cohort of pregnant population in China that longitudinally documents drug uses throughout the pregnancy life course and adverse pregnancy outcomes. The main goal of the study aims to monitor and evaluate the safety of drug use through the pregnancy life course in the Chinese setting. The DEEP cohort is developed primarily based on the population-based data platforms in Xiamen, a municipal city of 5 million population in southeast China. Based on these data platforms, a pregnancy-centered registry was developed that documented health care services and outcomes in the maternal and other departments. For identifying drug uses, a drug prescription database was specifically developed by using electronic healthcare records documented in the platforms across the primary, secondary and tertiary hospitals. By linking the pregnancy registry and prescription database through a unique identifier, the DEEP cohort was developed. All the pregnant women and their offspring in Xiamen are provided with health care and followed up according to standard protocols in the region, including antenatal care, delivery care, postpartum follow-up and childhood follow-ups. The primary adverse outcomes - congenital malformations - are collected using a standardized Case Report Form.

Interventions

DRUGchemicals drugs, biological products, patent Chinese Medicines, Chinese herbs

medication (i.e., chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs ) exposure through the pregnancy life course

Sponsors

Xiamen Health Commission
CollaboratorUNKNOWN
Xiamen Health and Medical Big Data Center
CollaboratorUNKNOWN
West China Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
14 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Pregnant women who registered at the Maternal and Child Health Management Platform in Xiamen.

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
congenital malformationsup to 42 days after deliveryNumber of births with congenital malformations

Secondary

MeasureTime frameDescription
preterm birthup to 37 gestational weeksNumber of pregnancies with preterm birth
low birth weightImmediately after deliveryNumber of live births with low birth weight

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026